AR077977A1 - Compuestos y composiciones como inhibidores de cinasa de proteina - Google Patents
Compuestos y composiciones como inhibidores de cinasa de proteinaInfo
- Publication number
- AR077977A1 AR077977A1 ARP100103125A ARP100103125A AR077977A1 AR 077977 A1 AR077977 A1 AR 077977A1 AR P100103125 A ARP100103125 A AR P100103125A AR P100103125 A ARP100103125 A AR P100103125A AR 077977 A1 AR077977 A1 AR 077977A1
- Authority
- AR
- Argentina
- Prior art keywords
- carbon atoms
- alkyl
- halogen
- substituted
- cycloalkyl
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Pain & Pain Management (AREA)
- Psychiatry (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Immunology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Las composiciones farmacéuticas de los mismos son utiles para el tratamiento de las enfermedades asociadas con B-Raf. Reivindicacion 1: Un compuesto de la formula (1) o (2): en donde: R1 es: (i) H, (ii) cicloalquilo (de 3 a 6 átomos de carbono) opcionalmente sustituido con ciano; (iii) alquilo (de 1 a 3 átomos de carbono) opcionalmente sustituido con ciano, -C(O)NH2, o hidroxilo, o (iv) -X1NHC(O)OR1a o -X1NHC(O)NHR1a, en donde X1 es alquileno (de 1 a 4 átomos de carbono) opcionalmente sustituido con 1 a 3 grupos, cada uno independientemente seleccionado a partir de halogeno, alquilo (de 1 a 4 átomos de carbono), o alquilo (de 1 a 4 átomos de carbono) sustituido por halogeno, y R1a es H, alquilo (de 1 a 4 átomos de carbono), o alquilo (de 1 a 4 átomos de carbono) sustituido por halogeno; R1b es H o metilo; R2 es H o halogeno; R3 es H, halogeno, alcoxilo (de 1 a 4 átomos de carbono), alquilo (de 1 a 4 átomos de carbono), alcoxilo (de 1 a 4 átomos de carbono) sustituido por halogeno, o alquilo (de 1 a 4 átomos de carbono) sustituido por halogeno; R4 es halogeno, H, o alquilo (de 1 a 4 átomos de carbono); R5 es alquilo (de 1 a 6 átomos de carbono), cicloalquilo (de 3 a 6 átomos de carbono), alquilo ramificado (de 3 a 8 átomos de carbono), alquilo (de 1 a 6 átomos de carbono) sustituido por halogeno, alquilo ramificado (de 3 a 8 átomos de carbono) sustituido por halogeno, cicloalquilo (de 3 a 6 átomos de carbono)-alquileno (de 1 a 3 átomos de carbono), o fenilo, en donde el fenilo está opcionalmente sustituido con 1 a 3 sustituyentes, cada uno independientemente seleccionado a partir de halogeno, CH3, o CF3; R6 es H, alquilo (de 1 a 4 átomos de carbono), o halogeno; y R7 es H, alquilo (de 1 a 6 átomos de carbono), cicloalquilo (de 3 a 6 átomos de carbono), 1-metil-cicloalquilo (de 3 a 6 átomos de carbono), alquilo ramificado (de 3 a 8 átomos de carbono), o fenilo, en donde el fenilo está opcionalmente sustituido con 1 a 3 sustituyentes seleccionados a partir de halogeno, alquilo (de 1 a 4 átomos de carbono) o alquilo (de 1 a 4 átomos de carbono) sustituido por halogeno; o una sal farmacéuticamente aceptable del mismo.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US23808309P | 2009-08-28 | 2009-08-28 | |
| US31306110P | 2010-03-11 | 2010-03-11 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR077977A1 true AR077977A1 (es) | 2011-10-05 |
Family
ID=42829939
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP100103125A AR077977A1 (es) | 2009-08-28 | 2010-08-26 | Compuestos y composiciones como inhibidores de cinasa de proteina |
Country Status (19)
| Country | Link |
|---|---|
| US (3) | US8242260B2 (es) |
| EP (1) | EP2470528B1 (es) |
| JP (1) | JP5726190B2 (es) |
| KR (1) | KR101714107B1 (es) |
| CN (1) | CN102596937B (es) |
| AR (1) | AR077977A1 (es) |
| AU (1) | AU2010288455B2 (es) |
| BR (1) | BR112012004448A2 (es) |
| CA (1) | CA2771673C (es) |
| EA (1) | EA020479B1 (es) |
| ES (1) | ES2527176T3 (es) |
| IN (1) | IN2012DN00869A (es) |
| JO (1) | JO3007B1 (es) |
| MX (1) | MX2012002542A (es) |
| PL (1) | PL2470528T3 (es) |
| PT (1) | PT2470528E (es) |
| TW (1) | TWI487701B (es) |
| UY (1) | UY32859A (es) |
| WO (1) | WO2011023773A1 (es) |
Families Citing this family (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JO3002B1 (ar) * | 2009-08-28 | 2016-09-05 | Irm Llc | مركبات و تركيبات كمثبطات كيناز بروتين |
| ES2576061T3 (es) | 2010-02-25 | 2016-07-05 | Dana-Farber Cancer Institute, Inc. | Mutaciones de BRAF que confieren resistencia a inhibidores de BRAF |
| WO2013059634A1 (en) | 2011-10-20 | 2013-04-25 | The Regents Of The University Of California | Use of cdk9 inhibitors to reduce cartilage degradation |
| CN108542906A (zh) | 2011-11-11 | 2018-09-18 | 诺华股份有限公司 | 治疗增生性疾病的方法 |
| MY172729A (en) | 2011-11-23 | 2019-12-11 | Array Biopharma Inc | Pharmaceutical formulations |
| US9408885B2 (en) | 2011-12-01 | 2016-08-09 | Vib Vzw | Combinations of therapeutic agents for treating melanoma |
| WO2014047330A1 (en) * | 2012-09-19 | 2014-03-27 | Jean-Michel Vernier | Novel raf kinase inhibitors |
| US9242969B2 (en) | 2013-03-14 | 2016-01-26 | Novartis Ag | Biaryl amide compounds as kinase inhibitors |
| WO2014194127A1 (en) * | 2013-05-30 | 2014-12-04 | Plexxikon Inc. | Compounds for kinase modulation, and indications therefor |
| UY35625A (es) | 2013-06-25 | 2014-12-31 | Bristol Myers Squibb Company Una Corporación Del Estado De Delaware | Compuestos de tetrahidrocarbazol y carbazol carboxamida sustituidos como inhibidores de quinasa |
| WO2014210087A1 (en) | 2013-06-25 | 2014-12-31 | Bristol-Myers Squibb Company | Carbazole carboxamide compounds useful as kinase inhibitors |
| KR20160067841A (ko) * | 2013-08-28 | 2016-06-14 | 메디베이션 테크놀로지즈, 인크. | 헤테로사이클릭 화합물 및 사용 방법 |
| GB2517988A (en) * | 2013-09-09 | 2015-03-11 | Redx Pharma Ltd | Compounds |
| UY36294A (es) | 2014-09-12 | 2016-04-29 | Novartis Ag | Compuestos y composiciones como inhibidores de quinasa |
| CA3000633C (en) | 2014-10-14 | 2023-10-03 | The Regents Of The University Of California | Use of cdk9 and brd4 inhibitors to inhibit inflammation |
| CN104402920B (zh) * | 2014-11-27 | 2018-04-03 | 河南科技学院 | 一种合成2‑卤代‑3‑频那醇硼酸酯‑5‑氯苯胺的方法 |
| BR112019005046A2 (pt) | 2016-09-19 | 2019-06-18 | Novartis Ag | combinações terapêuticas compreendendo um inibidor de raf e um inibidor de erk |
| EP3579872A1 (en) | 2017-02-10 | 2019-12-18 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods and pharmaceutical compositions for the treatment of cancers associated with activation of the mapk pathway |
| KR102641827B1 (ko) | 2017-05-02 | 2024-03-04 | 노파르티스 아게 | 병용 요법 |
| US11725185B2 (en) | 2017-12-28 | 2023-08-15 | University Of Houston System | Stem cell culture systems for columnar epithelial stem cells, and uses related thereto |
| WO2020124397A1 (en) * | 2018-12-19 | 2020-06-25 | Inventisbio Shanghai Ltd. | C-terminal src kinase inhibitors |
| EP3969449B1 (en) | 2019-05-13 | 2025-02-12 | Novartis AG | New crystalline forms of n-(3-(2-(2-hydroxyethoxy)-6-morpholinopyridin-4-yl)-4-methvlphenyl)-2(trifluoromethyl)isonicotinamide as raf inhibitors for the treatment of cancer |
| EP4196228A1 (en) * | 2020-08-13 | 2023-06-21 | Albert Einstein College of Medicine | N-cyclyl-sulfonamides useful for inhibiting raf |
| WO2023240024A1 (en) | 2022-06-08 | 2023-12-14 | Nikang Therapeutics, Inc. | Sulfamide derivatives as cyclin-dependent kinase 2 inhibitors |
Family Cites Families (25)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US2659739A (en) | 1950-04-14 | 1953-11-17 | Eastman Kodak Co | 1-hydroxy-4-beta-cyanopropylamino-anthraquinone and process for preparing same |
| US6391636B1 (en) | 1994-05-31 | 2002-05-21 | Isis Pharmaceuticals, Inc. | Antisense oligonucleotide modulation of raf gene expression |
| US6358932B1 (en) | 1994-05-31 | 2002-03-19 | Isis Pharmaceticals, Inc. | Antisense oligonucleotide inhibition of raf gene expression |
| US6037136A (en) | 1994-10-24 | 2000-03-14 | Cold Spring Harbor Laboratory | Interactions between RaF proto-oncogenes and CDC25 phosphatases, and uses related thereto |
| US5717100A (en) | 1995-10-06 | 1998-02-10 | Merck & Co., Inc. | Substituted imidazoles having anti-cancer and cytokine inhibitory activity |
| GB2306108A (en) * | 1995-10-13 | 1997-04-30 | Merck & Co Inc | Treatment of Raf-mediated cancers with imidazole derivatives |
| WO1997044058A1 (en) | 1996-05-23 | 1997-11-27 | Applied Research Systems Ars Holding N.V. | Compounds that inhibit the binding of raf-1 or 14-3-3 proteins to the beta chain of il-2 receptor, and pharmaceutical compositions containing same |
| AR012634A1 (es) | 1997-05-02 | 2000-11-08 | Sugen Inc | Compuesto basado en quinazolina, composicion famaceutica que lo comprende, metodo para sintetizarlo, su uso, metodos de modulacion de la funcion deserina/treonina proteinaquinasa con dicho compuesto y metodo in vitro para identificar compuestos que modulan dicha funcion |
| US6187799B1 (en) | 1997-05-23 | 2001-02-13 | Onyx Pharmaceuticals | Inhibition of raf kinase activity using aryl ureas |
| GB9716557D0 (en) | 1997-08-06 | 1997-10-08 | Glaxo Group Ltd | Benzylidene-1,3-dihydro-indol-2-one derivatives having anti-cancer activity |
| US6022884A (en) | 1997-11-07 | 2000-02-08 | Amgen Inc. | Substituted pyridine compounds and methods of use |
| US6204467B1 (en) | 1998-03-24 | 2001-03-20 | Ford Global Technologies, Inc. | Method and apparatus for resistive welding |
| US7351834B1 (en) | 1999-01-13 | 2008-04-01 | Bayer Pharmaceuticals Corporation | ω-Carboxyaryl substituted diphenyl ureas as raf kinase inhibitors |
| WO2002018654A1 (en) | 2000-08-30 | 2002-03-07 | The Board Of Trustees Of The University Of Arkansas | Induction of ldl receptor expression by extracellular-signal regulated kinase, erk-1/2 |
| CN101486682B (zh) | 2002-03-13 | 2013-08-14 | 阵列生物制药公司 | 作为mek抑制剂的n3烷基化苯并咪唑衍生物 |
| US6644516B1 (en) | 2002-11-06 | 2003-11-11 | Continental Afa Dispensing Company | Foaming liquid dispenser |
| CA2599212A1 (en) | 2005-02-25 | 2006-08-31 | Kudos Pharmaceuticals Limited | 2,4-diamino-pyridopyrimidine derivatives and their use as mtor inhibitors |
| WO2006090167A2 (en) | 2005-02-25 | 2006-08-31 | Kudos Pharmaceuticals Limited | Hydrazinomethyl, hydr zonomethyl and 5-membered heterocylic compounds which act as mtor inhibitors and their use as anti cancer agents |
| KR101464384B1 (ko) | 2005-11-22 | 2014-11-21 | 쿠도스 파마슈티칼스 리미티드 | ｍＴＯＲ 억제제로서 피리도피리미딘, 피라조피리미딘 및피리미도피리미딘 유도체 |
| AU2007204208A1 (en) | 2006-01-11 | 2007-07-19 | Astrazeneca Ab | Morpholino pyrimidine derivatives and their use in therapy |
| US7902189B2 (en) | 2006-08-23 | 2011-03-08 | Astrazeneca Ab | Compounds |
| TW200922582A (en) | 2007-08-20 | 2009-06-01 | Organon Nv | N-benzyl, N'-arylcarbonylpiperazine derivatives |
| WO2009115572A2 (en) | 2008-03-21 | 2009-09-24 | Novartis Ag | Novel heterocyclic compounds and uses therof |
| UA103319C2 (en) | 2008-05-06 | 2013-10-10 | Глаксосмитклайн Ллк | Thiazole- and oxazole-benzene sulfonamide compounds |
| CN102105459B (zh) * | 2008-07-24 | 2014-09-10 | 内尔维阿诺医学科学有限公司 | 作为蛋白激酶抑制剂的3,4-二芳基吡唑类 |
-
2010
- 2010-08-24 US US12/862,418 patent/US8242260B2/en not_active Expired - Fee Related
- 2010-08-26 AU AU2010288455A patent/AU2010288455B2/en not_active Ceased
- 2010-08-26 BR BR112012004448A patent/BR112012004448A2/pt not_active Application Discontinuation
- 2010-08-26 AR ARP100103125A patent/AR077977A1/es unknown
- 2010-08-26 EP EP10745280.7A patent/EP2470528B1/en active Active
- 2010-08-26 CN CN201080038235.XA patent/CN102596937B/zh active Active
- 2010-08-26 IN IN869DEN2012 patent/IN2012DN00869A/en unknown
- 2010-08-26 MX MX2012002542A patent/MX2012002542A/es active IP Right Grant
- 2010-08-26 PT PT107452807T patent/PT2470528E/pt unknown
- 2010-08-26 KR KR1020127007838A patent/KR101714107B1/ko active IP Right Grant
- 2010-08-26 PL PL10745280T patent/PL2470528T3/pl unknown
- 2010-08-26 WO PCT/EP2010/062495 patent/WO2011023773A1/en active Application Filing
- 2010-08-26 JO JOP/2010/0298A patent/JO3007B1/ar active
- 2010-08-26 JP JP2012526067A patent/JP5726190B2/ja active Active
- 2010-08-26 ES ES10745280.7T patent/ES2527176T3/es active Active
- 2010-08-26 CA CA2771673A patent/CA2771673C/en not_active Expired - Fee Related
- 2010-08-26 EA EA201200323A patent/EA020479B1/ru not_active IP Right Cessation
- 2010-08-27 TW TW099128938A patent/TWI487701B/zh not_active IP Right Cessation
- 2010-08-27 UY UY0001032859A patent/UY32859A/es not_active Application Discontinuation
-
2012
- 2012-05-16 US US13/473,230 patent/US8563553B2/en active Active
-
2013
- 2013-09-10 US US14/022,540 patent/US8859548B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| CA2771673A1 (en) | 2011-03-03 |
| US20110052578A1 (en) | 2011-03-03 |
| EA020479B1 (ru) | 2014-11-28 |
| JO3007B1 (ar) | 2016-09-05 |
| PT2470528E (pt) | 2014-12-29 |
| US20140011825A1 (en) | 2014-01-09 |
| EA201200323A1 (ru) | 2012-09-28 |
| EP2470528B1 (en) | 2014-10-01 |
| ES2527176T3 (es) | 2015-01-21 |
| JP2013503139A (ja) | 2013-01-31 |
| US8242260B2 (en) | 2012-08-14 |
| UY32859A (es) | 2011-03-31 |
| KR101714107B1 (ko) | 2017-03-08 |
| MX2012002542A (es) | 2012-04-02 |
| CA2771673C (en) | 2016-07-12 |
| PL2470528T3 (pl) | 2015-03-31 |
| AU2010288455B2 (en) | 2013-01-31 |
| AU2010288455A1 (en) | 2012-02-23 |
| US20120225899A1 (en) | 2012-09-06 |
| CN102596937A (zh) | 2012-07-18 |
| EP2470528A1 (en) | 2012-07-04 |
| KR20120092577A (ko) | 2012-08-21 |
| BR112012004448A2 (pt) | 2017-05-30 |
| TW201111365A (en) | 2011-04-01 |
| TWI487701B (zh) | 2015-06-11 |
| CN102596937B (zh) | 2014-02-12 |
| IN2012DN00869A (es) | 2015-07-10 |
| US8563553B2 (en) | 2013-10-22 |
| WO2011023773A1 (en) | 2011-03-03 |
| JP5726190B2 (ja) | 2015-05-27 |
| US8859548B2 (en) | 2014-10-14 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR077977A1 (es) | Compuestos y composiciones como inhibidores de cinasa de proteina | |
| AR072952A1 (es) | Compuestos de 2-imino-3-metilpirrolopirimidinona fenilo-sustituida como inhibidores de bace-1, composiciones y su uso | |
| AR077975A1 (es) | Derivados de pirazol pirimidina y composiciones como inhibidores de cinasa de proteina | |
| EA201690019A1 (ru) | Производное аминотриазина и содержащая его фармацевтическая композиция | |
| PE20140192A1 (es) | Derivados de bencimidazol como inhibidores de cinasa pi3 | |
| AR098912A1 (es) | Inhibidores de syk | |
| CY1118572T1 (el) | Παραγωγο κυκλοαλκανιου | |
| AR053120A1 (es) | Aminopiridinas como inhibidores de beta secretasa | |
| AR087668A1 (es) | Derivados de oxazina y su uso en el tratamiento de enfermedades | |
| AR078045A1 (es) | Derivados de pirimidina, composiciones farmaceuticas que los comprenden y su uso en la fabricacion de un medicamento para el tratamiento del cancer | |
| PE20160844A1 (es) | Compuestos triciclicos como agentes anticancerigenos | |
| EA200970510A1 (ru) | Гетеромоноциклическое соединение и его применение | |
| PE20141598A1 (es) | Derivados de dihidro-benzo-oxazina y dihidro-pirido-oxazina | |
| PE20110150A1 (es) | Amidofenoxiindazoles como inhibidores de c-met | |
| AR087915A1 (es) | N-(3-(2-amino-6,6-difluor-4,4a,5,6,7,7a-hexahidro-ciclopenta-[e][1,3]oxazin-4-il)-fenil)-amidas como inhibidores de la bace1 | |
| AR085615A1 (es) | Derivados de fluoropiridinona utiles como agentes antibacterianos y composiciones farmaceuticas que los contienen | |
| UY30498A1 (es) | Nueva clase de compuestos de benzimidazolilo, sus sales, composiciones farmacéuticas conteniéndolos y aplicaciones | |
| PE20141075A1 (es) | 4-aril-n-fenil-1,3,5-triazin-2-aminas que contienen un grupo sulfoximina | |
| AR080779A1 (es) | Pirrolopirazina como inhibidores quinasa, composiciones farmaceuticas que los contienen y sus aplicaciones | |
| AR051485A1 (es) | Pirazolo pirimidinas 1,4-sustituidas como inhibidores de quinasa | |
| PE20091694A1 (es) | DERIVADOS POLISUSTITUIDOS DE 6-HETEROARIL-IMIDAZO[1,2-a] PIRIDINAS COMO MODULADORES DE LOS RECEPTORES NOT Y SU PREPARACION | |
| EA201001682A1 (ru) | Производные фенил- и бензодиоксинилзамещенных индазолов | |
| PE20080409A1 (es) | Compuestos que modulan en el receptor cb2 | |
| PE20151601A1 (es) | Compuestos novedosos de pirimidina y piridina y su uso | |
| AR074089A1 (es) | Antagonistas de cicloalcano (b) azaindol de los receptores de la postaglandina d2 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FB | Suspension of granting procedure |